Alkem Labs Launches Semaglutide Injection in India Starting at ₹450/Week
Alkem Laboratories has launched semaglutide injection in India for type-2 diabetes and weight management. The weekly therapy starts at ₹450, with a month's dosage priced at ₹1,800. The company received DCGI approval and aims to improve access to this treatment.
The launch of a new drug in a significant therapeutic area can positively impact the company's revenue and market share, but the long-term financial impact will depend on market adoption and competition.
The launch of a new, affordable medication for a significant health condition like type-2 diabetes and chronic weight management is a positive development for the company and patients.
Alkem Laboratories Limited has announced the launch of its semaglutide injection in India, a once-weekly therapy for type-2 diabetes mellitus and chronic weight management. The product is available under the brand names "Semasize", "Obesema", and "Hepaglide".
The company is offering a pre-filled disposable injection pen containing four doses for a month, with prices starting at ₹1,800, which translates to a weekly cost of ₹450. This pricing strategy aims to make the therapy more accessible in India.
Alkem has received approval from the Drug Controller General of India (DCGI) for manufacturing and marketing semaglutide, following successful Phase 3 clinical trials conducted in India. The injection is administered subcutaneously and requires medical supervision.
In addition to the disposable pen, Alkem is also providing a reusable injection pen option for higher maintenance doses. This reusable pen allows patients to replace only the medication cartridge, potentially reducing costs and improving treatment adherence.
Dr. Vikas Gupta, Chief Executive Officer of Alkem, commented, "We believe therapeutic advancements must translate into real-world access to create a lasting impact. With the launch of our indigenously-developed semaglutide, we are bringing a high-quality and affordable option to market, empowering healthcare practitioners to offer this therapy to more deserving patients."
What to do with a filing like this
Alkem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under product launches. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alkem Laboratories Limited. Read the original for the full detail.